Millions of Americans Face Skyrocketing Prices for Canadian Medications Due to New Federal Rule

Millions of Americans who rely on cheap prescription medication from Canada could face skyrocketing prices due to a new federal rule that's set to take effect later this month.

The rule, implemented by the U.S. Customs and Border Protection, targets goods beyond just medications, aiming to collect tariffs and prevent illicit substances from entering the country. Critics argue that the move will have a disproportionate impact on patients seeking affordable treatment, particularly those who require complex and expensive medications.

For Susan Hooper, 75-year-old resident of Toledo, Ohio, the issue is a matter of life and death. She has been using oxygen for 14 years and relies on two daily medications purchased from a Canadian pharmacy that are not available in the U.S.

The rule specifically targets the de minimis exemption, which previously allowed shipments valued under $800 to pass through customs with relative ease. As of October 22, this exemption will be indefinitely suspended, requiring medications mailed from outside the U.S. to undergo additional scrutiny and potentially come with a bond guarantee.

The rule change, aimed at simplifying customs procedures, has an unexpected consequence: it may make it harder for millions of Americans who rely on cheap medications from Canada to access them.

While not specifically targeting Canadian drugs, the revised regulations apply broadly to international mail shipments, which could lead to delays or refusals in delivering these essential medicines.

According to a 2020 study by JAMA Network, approximately 2.3 million Americans buy their prescription drugs abroad, and this rule change may significantly impact them.

The Trump administration has made lowering drug prices a priority, but the new regulations may undermine some of its efforts to address soaring costs, as it could lead to higher prices for those who rely on imported medications.

The new federal rule is set to have far-reaching consequences for millions of Americans who rely on affordable medications from Canada.

According to Ken Hunter, executive director of the Campaign for Personal Prescription Importation, patients seeking lower drug prices may not benefit from Trump's initiatives. This is because many of these programs only cover a limited range of conditions and medications, leaving out those who need more specialized treatments.

The organization conducted a study in August on 10 commonly prescribed medications imported from Canada, revealing that some costs will skyrocket for certain medications once the new rule takes effect. For instance, Eliquis, a prescription blood thinner used to prevent and treat blood clots, would cost $565 for a three-month supply of 180 pills from a Canadian mail order pharmacy.

However, under the new regulations, this same medication could be as expensive as $1,017 or $1,029 when purchased through Amazon's pharmacy arm or GoodRx.

The Trump administration's new regulations on prescription drugs have sparked concerns among lawmakers who fear that millions of Americans will be priced out of affordable medication.

Florida Republican Congress members Aaron Bean, Gus M. Bilirakis, and C. Scott Franklin have written to the administration expressing their worries about how the rule will impact their constituents. They pointed out that unlike residents of border states, many Floridians rely on imported medications from Canada due to high domestic prices.

The lawmakers emphasized that Customs and Border Protection and the Food and Drug Administration must ensure that individuals seeking relief from high drug costs are not inadvertently affected by the new regulations. They called for clarification on how the administration plans to protect access to affordable care for people who rely on cross-border medication purchases.

Florida has already taken steps to address its residents' prescription needs, having crafted a Canadian prescription drug importation program with federal authorization. However, this initiative remains stalled and awaits resolution amidst the ongoing regulatory changes.

The new federal rule is set to impact millions of Americans who rely on affordable prescription medications from Canada, with prices potentially soaring due to stricter regulations.

A group of 70 Democrats has intervened, urging health and immigration officials to suspend the rule until they can provide assurances that personal use medicines will still be allowed into the country. The lawmakers argue that Americans should not lose access to essential treatments simply because the government is seeking better information on packages entering the US.

The proposed rule change comes as an added blow to those who already struggle with high medication costs, like Sarah Hooper, who suffers from serious drug allergies and relies on Canadian imports for her treatment. Her medications have already seen significant price hikes since the Trump administration imposed additional tariffs in August, with Theophylline increasing from $85 to $141 and Foradil rising from $151 to $273.

As a result of these price increases, Hooper has been stockpiling her medication until she can find an alternative solution.